厄贝沙坦联合胺碘酮治疗心衰并发室性心律失常临床效果探讨.docVIP

厄贝沙坦联合胺碘酮治疗心衰并发室性心律失常临床效果探讨 　　[摘要] 目的 研究厄贝沙坦联合胺碘酮治疗心衰并发室性心律失常的临床效果。 方法 随机选取2015年10月―2016年10月该院心衰并发室性心律失常患者80例，随机分2组，每组40例，对照组胺碘酮片，观察组再给予厄贝沙坦，对比两组患者的室性心律失常、心功能以及治疗后的HR、 LVEF情况。结果 观察组心衰并发室性心律失常患者心功能的总有效率为92.50%，室性心律失常控制有效率为87.50%，治疗效果明显优于对照组，差异有统计学意义（P0.05）。观察组治疗后HR情况为（72.65±4.32）次/min，LVEF情况为（50.66±6.49）%，观察组心衰并发室性心律失常患者的HR、LVEF情?r明显优于对照组，差异有统计学意义（P0.05）。结论 厄贝沙坦联合胺碘酮治疗的安全性高，在临床治疗效果中显著，适用于心衰并发室性心律失常的治疗。 　　[关键词] 心衰并发室性心律失常；厄贝沙坦；胺碘酮 　　[中图分类号] R541.6 [文献标识码] A [文章编号] 1674-0742（2017）02（b）-0125-03 　　[Abstract] Objective To research the clinical effect of irbesartan and amiodarone in treatment of heart failure and ventricular arrhythmias. Methods Random selection 80 cases of patients with heart failure and ventricular arrhythmias admitted and treated in our hospital from October 2015 to October 2016 were selected and randomly divided into two groups with 40 cases in each， the control group were treated with amiodarone tablets， while the observation group were treated with irbesartan， and the ventricular arrhythmias， heart function and HR and LVEF after treatment were compared between the two groups. Results The total effective rate of heart function of patients with heart failure and ventricular arrhythmias in the observation group was obviously better than that in the control group（92.50% vs 87.50%）， and the difference had statistical significance（P0.05）， and the HR and LVEF after treatment in the observation group[（72.65±4.32）times/min，（50.66±6.49）%] were obviously better than those in the control group， and the differences had statistical significance（P0.05）. Conclusion The safety of irbesartan and amiodarone in treatment of heart failure and ventricular arrhythmias is high， and the clinical treatment effect is obvious， which is suitable for the treatment of heart failure and ventricular arrhythmias. 　　[Key words] Heart failure and ventricular arrhythmias； Irbesartan； Amiodarone 　　慢性心力衰竭是多种心脏病发展的最终阶段，易并发室心律失常，由于疾病的危险性，如果不及时治疗，会发生血液流变学障碍或更进一步发展为室颤、持续性室速，严重者则引发生命危险[